Department of Clinical Laboratory, Fujian Provincial hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East street, Gulou District, Fuzhou, 350001, China.
Department of Thoracic Surgery, Fujian Provincial hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East street, Gulou District, Fuzhou, 350001, China.
BMC Cancer. 2022 Jul 30;22(1):834. doi: 10.1186/s12885-022-09930-5.
Cancer-testis antigens (CTAs) have emerged as potential clinical biomarkers targeting immunotherapy. KK-LC-1 is a member of CTAs, which has been demonstrated in a variety of tumors tissues and been found to elicit immune responses in cancer patients. However, the expression level and immune infiltration role of KK-LC-1 in lung adenocarcinoma (LUAD) remains to be elucidated.
In this study, the mRNA expression and overall survival rate of KK-LC-1 were evaluated by the TIMER and TCGA database in LUAD tissues and KK-LC-1 expression was further validated by clinical serum samples using quantitative RT-PCR. The relationship of KK-LC-1 with clinicopathologic parameters was analyzed. ROC curve result showed that miR-1825 was able to distinguish preoperative breast cancer patients from healthy people and postoperative patients. Then, the ROC curves were used to examine the ability of KK-LC-1 to distinguish preoperative LUAD patients from healthy and postoperative patients. The correlation between KK-LC-1 and infiltrating immune cells and immune marker sets was investigated via TIMER, TISIDB database, and CIBERSORT algorithm. The Kaplan-Meier plotter was used to further evaluate the prognostic value based on the expression levels of KK-LC-1 in related immune cells.
The results showed that KK-LC-1 was significantly over-expressed in LUAD, and high levels of expression of KK-LC-1 were also closely correlated with poor overall survival. We also found that KK-LC-1 associated with TMN stage, NSE and CEA. The ROC curve result showed that KK-LC-1 was able to distinguish preoperative LUAD cancer patients from healthy people and postoperative patients. Moreover, KK-LC-1 had a larger AUC with higher diagnostic sensitivity and specificity than CEA. Based on the TIMER, TISIDB database, and CIBERSORT algorithm, the expression of KK-LC-1 was negatively correlated with CD4+ T cell, Macrophage, and Dendritic Cell in LUAD. Moreover, Based on the TIMER database, KK-LC-1 expression had a remarkable correlation with the type markers of Monocyte, TAM, M1 Macrophage, and M2 Macrophage. Furthermore, KK-LC-1 expression influenced the prognosis of LUAD patients by directly affecting immune cell infiltration by the Kaplan-Meier plotter analysis.
In conclusion, KK-LC-1 may serve as a promising diagnostic and prognostic biomarker in LUAD and correlate with immune infiltration and prognosis.
癌症睾丸抗原(CTAs)已成为免疫治疗的潜在临床生物标志物。KK-LC-1 是 CTAs 的成员,已在多种肿瘤组织中得到证实,并在癌症患者中发现能引发免疫反应。然而,KK-LC-1 在肺腺癌(LUAD)中的表达水平和免疫浸润作用仍有待阐明。
在这项研究中,通过 TIMER 和 TCGA 数据库评估 LUAD 组织中 KK-LC-1 的 mRNA 表达和总生存率,并使用定量 RT-PCR 进一步验证临床血清样本中 KK-LC-1 的表达。分析 KK-LC-1 与临床病理参数的关系。ROC 曲线结果表明,miR-1825 能够区分术前乳腺癌患者与健康人和术后患者。然后,使用 ROC 曲线来检验 KK-LC-1 区分术前 LUAD 患者与健康人和术后患者的能力。通过 TIMER、TISIDB 数据库和 CIBERSORT 算法研究 KK-LC-1 与浸润免疫细胞和免疫标志物集的相关性。使用 Kaplan-Meier 绘图器根据相关免疫细胞中 KK-LC-1 的表达水平进一步评估预后价值。
结果表明,KK-LC-1 在 LUAD 中显著过表达,高水平的 KK-LC-1 表达也与总体生存率密切相关。我们还发现 KK-LC-1 与 TMN 分期、NSE 和 CEA 相关。ROC 曲线结果表明,KK-LC-1 能够区分术前 LUAD 癌症患者与健康人和术后患者。此外,KK-LC-1 的 AUC 较大,诊断灵敏度和特异性均高于 CEA。基于 TIMER、TISIDB 数据库和 CIBERSORT 算法,在 LUAD 中,KK-LC-1 的表达与 CD4+T 细胞、巨噬细胞和树突状细胞呈负相关。此外,基于 TIMER 数据库,KK-LC-1 的表达与单核细胞、TAM、M1 巨噬细胞和 M2 巨噬细胞的典型标志物有显著相关性。此外,通过 Kaplan-Meier 绘图器分析,KK-LC-1 的表达通过直接影响免疫细胞浸润,影响 LUAD 患者的预后。
综上所述,KK-LC-1 可能成为 LUAD 有前途的诊断和预后生物标志物,与免疫浸润和预后相关。